Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio

Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio
复制标题

DOI:
10.1002/hed.24224
复制
发表时间:
2016-04-01
影响因子:
2.9
通讯作者:
Hu, Guoqing
Hu, Guoqing
中科院分区:
医学2区
文献类型:
--
作者:
Sun, Wei;Zhang, Linli;Hu, Guoqing

文献摘要

被引文献

相似文献

背景炎症反应的治疗前血液学标志物已成为癌症患者的预后因素。本研究旨在探讨血液学指标对鼻咽癌患者预后的影响。回顾性分析251例鼻咽癌患者的临床资料。采用中性粒细胞计数、淋巴细胞计数、血小板计数、嗜中性粒细胞-淋巴细胞比率(NLR)和血小板-淋巴细胞比率(PLR)作为潜在的预后生物标志物。采用Kaplan-Meier法和log-rank检验计算并比较两组患者的无进展生存期(PFS)和总生存期(OS)。采用考克斯比例风险模型进行单因素和多因素分析。NLR >= 2.7(风险比[HR] = 2.01; 95%置信区间[CI] 51.23-3.29; p=.005)和PLR >= 167.2(HR=2.12; 95% CI=1.35-3.33; p= 0.001)与PFS缩短显著相关,而PLR >= 163.4(HR=2.64; 95% CI=1.25-5.60; p= 0.011)与OS差相关。治疗前NLR和PLR可作为鼻咽癌患者的独立预后因素。(C)2015年Wiley期刊,
Background. Pretreatment hematological markers of inflammatory response have emerged as prognostic factors for patients with cancer. In this study, we evaluated the prognostic significance of various hematologic parameters in patients with nasopharyngeal carcinoma (NPC).Methods. Clinical data from 251 patients with NPC were retrospectively collected. Neutrophil counts, lymphocyte counts, platelet counts, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) were adopted as potential prognostic biomarkers. The Kaplan-Meier method and log-rank test were adopted to calculate and compare the progression-free survival (PFS) and overall survival (OS) rates. The Cox proportional hazards model was used to carry out univariate and multivariate analyses.Results. NLR >= 2.7 (hazard ratio[HR] = 2.01; 95% confidence interval [CI] 51.23-3.29; p=.005) and PLR >= 167.2 (HR=2.12; 95% CI=1.35-3.33; p=.001) were significantly associated with shorter PFS, whereas PLR >= 163.4 (HR=2.64; 95% CI=1.25-5.60; p=.011) was correlated with poor OS.Conclusion. Pretreatment NLR and PLR can be independent prognostic factors for patients with NPC. (C) 2015 Wiley Periodicals,